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PREFACE
The main body of this thesis in Chapter 3 is a journal article entitled “Modified
Chitosan Paste for Infection Prevention: Material and Functional Testing.” This
manuscript will be submitted to the journal of Clinical Orthopaedics and Related
Research.
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ABSTRACT
Rhodes, Cheyenne Starr. MS. The University of Memphis. December, 2015.
Characterization and Functional Evaluation of an Adhesive and Injectable Polyethylene
Glycol Modified Chitosan Paste for Infection Prevention. Major Professor: Warren O.
Haggard, PhD.
Musculoskeletal infections often result in multiple surgeries and increased cost for
the patient, and can be especially difficult to treat if infectious bacteria are biofilmforming or antibiotic-resistant. This research evaluated a series of paste formulations,
based on chitosan and polyethylene glycol (PEG) modified chitosan products combined
in 70:30 to 30:70 ratios, to locally deliver antibiotics for early abatement of infection as a
potential adjunctive therapy. Paste formulations were evaluated for injectability, adhesive
properties, and in vitro degradability, cytocompatibility, and antibiotic release and
activity as compared to a neutral chitosan sponge control. The paste formulations were
also compared to the control sponge for ability to prevent infection in a murine catheter
model. Blending PEG into the chitosan paste formulation allowed the 50:50 and 40:60
pastes to remain injectable through a syringe and adhesive to tissue while increasing in
vitro biocompatibility. Compared to the sponge control, in vitro degradation of the paste
was increased and antibiotic release was extended, resulting in extended active
antimicrobial activity. The 50:50 and 40:60 chitosan/PEG pastes also displayed improved
in vivo bacterial contamination prevention over the unmodified paste and sponges by
clearing all bacteria from catheters implanted in an infected mouse model. These
experimental results support the potential of the 50:50 and 40:60 pastes for use as a local
adjunctive antibiotic delivery system for musculoskeletal infections.
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CHAPTER 1
INTRODUCTION

Statement of Clinical Problem
Complex musculoskeletal wounds are one of the most prevalent types of injuries
in the United States, and can be complicated with the establishment of a bacterial
infection which can impair wound healing, be more challenging to treat, and result in
longer treatment time and higher number of surgeries, costs, and patient morbidity [7]. A
complex musculoskeletal wound has an estimated 20% chance in a civilian [7, 24, 55]
and as high as a 65% chance of becoming infected in a soldier if their wound is an open
fracture caused by high-energy trauma [24, 69]. Infections can be complicated even
further when antibiotic resistant and/or biofilm forming bacterial strains are present, such
as Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) [13,
20, 24]. Increasing systemic antibiotic levels to clear localized bacteria can cause adverse
side effects [29], and current local drug delivery devices either have little to no
degradation, requiring additional surgery for removal [27, 39], or rapid degradation,
causing excessive fluid accumulation and wound drainage [54]. The development of a
biocompatible and completely degradable local antibiotic delivery system whose drug
release could be tailored to individual patient need and surgeon preference and is
injectable for ease of use, adhesive to minimize wound migration, and conformable to
provide superior wound coverage would allow for increased antibiotic levels directly to
the injured wound site and provide a more effective remedy for infection control.
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Hypothesis and Research Objectives
We hypothesize that modifying chitosan paste with polyethylene glycol (PEG)
will improve the biocompatibility and biodegradability of this local drug delivery system
as compared to chitosan paste without PEG. Our other goals include maintaining
adhesiveness to minimize implant migration, injectability for ease of use, and capability
of point-of-care loading of various antibiotics to remain active against and prevent the
establishment of bacterial infections in musculoskeletal injuries. The specific objectives
of this research study are as follows:
1. Characterize and refine the range of functional chitosan/PEG paste variations
based on ratios of acidic chitosan and neutral chitosan/PEG products
2. Ensure reliable, easy injectability and tissue adhesivity of the modified
chitosan/PEG paste
3. Evaluate the in vitro degradation profile of the modified chitosan/PEG paste
over 10 days and potential cytotoxic effects it may have on cells after 72 hours
of exposure
4. In vitro delivery of vancomycin and amikacin from the modified
chitosan/PEG paste sustained through 72 hours at active levels against S.
aureus and P. aeruginosa, respectively, to prevent colonization
5. In vivo delivery of vancomycin from the modified chitosan/PEG paste over 48
hours for prevention of bacterial infection caused by biofilm forming S.
aureus in a functional mouse model
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CHAPTER 2
LITERATURE REVIEW

Musculoskeletal Wounds
A musculoskeletal wound occurs when damage to bone and muscle tissue
prevents their natural function [35]. A musculoskeletal injury can be caused by severe
crush, burn, puncture, laceration, or surgical incision and can occur in the civilian or
military population [11]. An estimated 1 in 10 American civilians will visit a hospital
every year due to a musculoskeletal wound [11] while American soldiers have
experienced over 50,000 just during Operations Iraqi Freedom and Enduring Freedom
[47]. Musculoskeletal wounds are one of the most prevalent types of injuries in the
United States, accounting for more than three out of five of the unintentional injuries per
year [7] and being among the leading causes of death in all age groups in the U.S. [11].
Every year billions of dollars are spent to treat musculoskeletal injuries in both the
civilian and military populations [26], with the average cost per hospitalized civilian
admitted for a musculoskeletal wound being $25,000 in 2004 [7].
Wound Management
Assessing and managing complex musculoskeletal wounds in a timely manner is
key to decreasing the risks of infection, amputation, and nonunion while increasing
healing and the patients’ quality of life [48]. Standard treatment for complex,
musculoskeletal wounds includes emergency first aid, systemic antibiotic therapy,
debridement, irrigation, fixation, closure, and dressings [48]. Systemic antibiotic therapy
should begin immediately in the emergency room followed by debridement and irrigation
to remove debris, other foreign contaminates, and nonviable tissue in order to reduce the

3

bacterial load and provide a wound bed healthy enough for closure [48]. The
musculoskeletal wound is then stabilized through internal or external fixation and closed
[17, 48]. Moist dressings to promote healing and angiogenesis can be applied externally
after wound closure or be packed into the wound if a delayed closure is necessary [48].
Antibiotics are continued to be given intravenously in case an infection is present;
however, this can be ineffective if the vasculature around the complex wound site is
damaged [29, 48, 55].
Wound Complications
The vasculature around a musculoskeletal wound site is often compromised,
which can lead to a severe reduction in systemic antibiotic distribution as well as the
amount of immune cells capable of reaching and healing the wound [29, 55]. An
inadequate number of immune cells and failure to deliver the proper dosage of antibiotics
allows contaminating bacteria to proliferate, resulting in an established musculoskeletal
wound infection [29, 55]. A complex musculoskeletal wound has an estimated 20%
chance of becoming infected in a civilian [7, 24, 55] while there is an estimated 26.5%
chance of one becoming infected in a soldier [26, 55] with an increase to 65% if their
wound is an open fracture [24, 69]. Open fractures, typically caused by high-energy
trauma such as gunshots or explosives, are especially susceptible to infections in the bone
and surrounding soft tissue [28, 43, 47]. Musculoskeletal infections severely impair
wound healing and can be very difficult to treat, many times resulting in increased
number of surgeries, treatment and rehabilitation time, costs, and patient morbidity [7].
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Wound Infection Complications
Musculoskeletal infections can be complicated even further when antibiotic
resistant and/or biofilm forming bacterial strains are present, such as S. aureus and P.
aeruginosa [13, 20, 24]. Antibiotic resistant bacteria are formed through high adaptation
and sharing DNA amongst themselves, and their resistance is increasing through the
commonality of world travel and the sheer volume of antibiotics used across the globe [3,
4, 31]. While bacterial resistance was initially confined to hospitalized patients, it has
since become increasingly more common for community-acquired infections as well [3].
Biofilm forming bacteria are equipped with protective mechanisms to resist antibacterial
agents including the abilities to communicate amongst themselves and reduce their
metabolic activity, resulting in the need for higher concentrations of systemic antibiotics
[16, 22]. Increasing the level of systemic antibiotics used can help clear the localized
bacteria in the infection, but not without causing adverse side effects [29]; therefore, a
local antibiotic delivery system should be used to increase antibiotic levels directly to the
injured wound site without compromising the integrity of the patient [22].
Current Local Drug Delivery Devices
There are multiple biomaterials currently being used as local drug delivery
devices; however, they still have many detrimental obstacles to overcome including
incomplete or no degradation requiring additional surgery to remove the remainder of the
device [27, 39], rapid degradation causing excessive ion release and fluid accumulation
[54], and the inability to be loaded at point-of-care by a surgeon with his/her choice of
antibiotics [14]. Polymethylmethacrylate (PMMA) is used as non-degradable bone
cement and is currently one of the most common biomaterials used as a local drug
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delivery system for musculoskeletal injuries [2, 27, 44]. PMMA mixed with antibiotics
has been shown to reduce infections in musculoskeletal wounds while acting as a spacefiller to stabilize the complex fracture; however, the PMMA loses material strength and
more readily fractures when antibiotics are added [2]. Another disadvantage of PMMA is
that it is not biodegradable and must be surgically removed for complete wound healing
to occur [27, 39].
Calcium sulfate is a biocompatible ceramic commonly used as another type of
bone space-filler and as a local drug delivery system for musculoskeletal wounds [2, 62].
Unlike PMMA, calcium sulfate is completely biodegradable and aids in bone
regeneration; however, calcium sulfate tends to have a rapid resorption rate which can
result in sub-par formation of new tissue, an express release of antibiotics quickly leaving
only sub-inhibitory levels to try to prevent or treat infections, and increased wound
drainage [2, 54, 62]. Developing an alternative local drug delivery device made from
chitosan could potentially provide the ideal local drug delivery system that is
biocompatible, completely degradable, provides an adequate drug release profile, and can
be loaded at point-of-care with a multitude of antimicrobials [46, 49-51, 58].
Chitosan
Chitosan has many advantageous properties including biodegradability, high
biocompatibility, bioadhesivity to hard and soft tissue, reactive side groups that allow it
to be easily modified, low cost, and high availability [2, 19]. Because of these favorable
qualities, chitosan has been researched to aid in drug delivery systems, tissue engineering
scaffolds, and wound dressings and has shown promise in contributing to these
biomedical applications [2, 19].
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Chitosan is derived from deacetylated chitin and is a naturally occurring,
positively charged, linear polysaccharide that is composed of β-(1-4)-2-amino-2-Dglucosamine (deacetylated) and β-(1-4)-2-acetamido-2-D-glucosamine (acetylated) units
[2, 19]. Chitin, which is the second most abundant natural polymer, is found in
exoskeletons of crustaceans, cuticles of insects, and cell walls of various fungi with the
major commercial source being acquired from the millions of tons of waste generated
from shrimp, crab, and lobster shells [2, 19]. Chitosan is distinguished from chitin by its
degree of deacetylation (DDA), where chitosan has more than 50% and chitin has less
than 50% of their respective acetyl functional groups removed [2]. Varying the degree of
deacetylation of chitosan can alter its properties; as DDA is increased, chitosan becomes
more soluble and biocompatible but does not degrade as rapidly [19]. Chitosan is soluble
in diluted acid solutions and interacts more with surrounding cells, which increases cell
adhesion and cell proliferation [19]. While chitosan may cause an acute inflammatory
response when the degradation rate in increased, decreasing the degradation rate can
reduce this inflammatory response to a minimum [19]. In the human body, chitosan can
be degraded chemically through acid catalyzed degradation or enzymatically through
depolymerization [19, 65]. Enzymatic degradation in the human body occurs mostly by
lysozyme, which has also been shown to degrade chitosan at high levels in vitro [57, 65].
Lysozyme hydrolyzes chitosan’s glycosidic bonds into glucosamine and saccharide
byproducts, both of which are compatible and can be absorbed gradually back into the
human body [15, 19].
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Chitosan as a Local Drug Delivery Device
Chitosan has been shown to be effective as a drug delivery system that can carry
antibiotics, release stored drugs over time at a predictable rate, and degrade efficiently
[19, 45]. While elution rates are predictable, degradation rates are widely varied; Stinner
et al. found that chitosan used as a wound dressing degraded rapidly [58] but Ma et al.
showed that chitosan implanted subcutaneously as a scaffold degraded nominally [38].
Multiple variations of chitosan devices designed for medical applications have been
researched at the University of Memphis including membranes as scaffolds for guided
bone regeneration [9], coatings and films loaded with growth factors and/or antibiotics to
apply on implants [36, 56], beads loaded with antibiotics and growth factors to improve
bone scaffolds [53], sponges loaded with antibiotics and/or antifungals for wound
dressings [46, 49, 52, 58], and paste developed from these sponges to also be used for
drug delivery [57].
Chitosan Sponges Modified with Polyethylene Glycol
The neutral chitosan sponges initially developed were porous, degradable, and
biocompatible to provide an adaptable drug delivery device that can be loaded with
clinician selected antibiotics at point-of-care [46, 58]. More recent chitosan sponges
developed at the University of Memphis have been modified with PEG [50, 51], a water
soluble polymer that can act as a solvent system allowing the sponge to additionally be
loaded with hydrophobic biofilm dispersants, such as cis-2-decenoic acid [32], or
antifungals, such as amphotericin B [18, 41, 42, 50, 51, 64].
Polyethylene glycol has many valuable, inherent qualities including low
immunogenicity and protein resistance as well as enhanced cell adhesion, cell growth,
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cell proliferation, and protein adsorption when added to chitosan films [70]. Parker et al.
has also shown that chitosan sponges modified with PEG have increased
biocompatibility, biodegradability, elution, and activity in laboratory studies compared to
the neutral chitosan sponges initially developed [50, 51].
Chitosan Sponges Modified into Chitosan Paste
Chitosan paste is also biocompatible and biodegradable like the initial neutral
chitosan sponges formulated, but was developed to further improve upon them by adding
the material properties of injectability, for easy application, and adhesivity, to prevent
migration of the device from the wound site. This conformable paste would provide
complete wound coverage, even in miniscule crevices between contaminated tissues, thus
leading to more effective drug diffusion.
To date, the in vitro research concerning an injectable, drug delivery device made
from chitosan shows that further investigation is required to enhance the functionality of
the device [1, 5, 6, 8, 21, 40, 57, 59, 60]. Previous in vivo soft tissue response studies also
showed highly variable degradation rates of an injectable, chitosan drug delivery device
[21, 40] that could induce a mild to moderate inflammatory response in animal models
[57, 59]. Preliminary in vitro studies on chitosan paste at the University of Memphis by
Smith et al. has shown that the paste is readily degradable, adhesive, and active against
bacteria but is only injectable and biocompatible when its acetic acid concentration is
between 15 and 35 μM [57]. Smith et al. also reported that the chitosan paste elicited a
slightly higher immune response than the neutral sponges in rats, but did eliminate more
bacteria than the neutral sponges in an infected wound with a polymer catheter simulating
an implant in mice [57].
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Current Work: Chitosan Paste Modified with Polyethylene Glycol
For the paste device investigated in this body of work, the acidic 1% chitosan
sponges used by Smith et al. to formulate the paste remained the same. The neutralized
1% chitosan sponges used by Smith et al. in the paste formulation, however, were
modified with PEG, as performed by Parker et al., to improve the paste’s in vitro
biocompatibility and degradation [50, 51, 57]. To address the first four objectives, both
acetic acid and PEG blended chitosan sponges were fabricated and combined in various
ratios to evaluate the in vitro biocompatibility, degradability, injectability, adhesivity, and
antibiotic elution and activity of multiple chitosan/PEG paste variations. Lastly, the
modified chitosan/PEG paste was also visually assessed for in vivo biocompatibility and
examined to confirm its ability to prevent the establishment of a biofilm forming bacterial
infection.

10

CHAPTER 3
MODIFIED CHITOSAN PASTE FOR INFECTION PREVENTION: MATERIAL
AND FUNCTIONAL TESTING

Introduction
A musculoskeletal injury can occur in civilian or military populations; an
estimated 1 in 10 American civilians will visit a hospital every year due to a
musculoskeletal wound [11] while American soldiers have experienced over 50,000 just
during Operations Iraqi Freedom and Enduring Freedom [47]. Musculoskeletal wounds
are one of the most prevalent types of injuries in the United States, accounting for more
than 60% of the unintentional injuries per year [7] and being among the leading causes of
death in all age groups in the U.S. [11]. Assessing and managing complex
musculoskeletal wounds in a timely manner is key to decreasing the risks of infection,
amputation, and nonunion while increasing healing and the patients’ quality of life [48].
Standard treatment for complex, musculoskeletal wounds includes emergency first aid,
debridement, irrigation, fixation, and systemic antibiotic therapy [48]. However, if the
vasculature around a wound is compromised, systemic antibiotic distribution will be
severely reduced allowing the proliferation of contaminating bacteria and the
establishment of a musculoskeletal wound infection [29, 55]. A complex musculoskeletal
wound has an estimated 20% chance of becoming infected in a civilian [7, 24, 55] while
there is a potential increase to 65% chance for soldiers suffering an open fracture [24,
69]. Musculoskeletal infections severely impair wound healing [7] and can be
complicated even further when antibiotic resistant and/or biofilm forming bacterial
strains are present, such as Staphylococcus aureus and Pseudomonas aeruginosa [13, 20,
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24], resulting in the need for higher concentrations of systemic antibiotics [22].
Increasing the level of systemic antibiotics used can help clear the infection, but not
without causing adverse side effects [29]; therefore, a local antibiotic delivery system is
ideal to increase local antibiotic levels without increasing complication risk to the patient
[22].
There are multiple biomaterials currently being used as local drug delivery
devices including Polymethylmethacrylate (PMMA) and calcium sulfate; however, they
still have many limitations including no degradation requiring additional surgery to
remove the device [27, 39], excessive ion release and fluid accumulation due to rapid
degradation [54], and limited antibiotic choice at point-of-care by the surgeon [14].
Developing a local drug delivery device that is biocompatible, completely degradable,
provides an adequate drug release profile, and can be loaded at point-of-care with a
multitude of antimicrobials would provide enhanced treatment over current devices [46,
49-51, 58].
In previous studies, chitosan/PEG sponges and chitosan paste were developed for
this purpose [46, 49-51, 57, 58]; however, both have shortcomings including incomplete
wound coverage and implant migration for the sponges [34, 58] and non-optimal
biocompatibility and incomplete in vivo degradation for the paste [57]. Our laboratory
has fabricated a chitosan paste modified with PEG to improve the paste’s
biocompatibility, biodegradability, and antibiotic delivery properties [50, 51, 57].
Chitosan is derived from deacetylated chitin and is a naturally occurring,
positively charged, linear polysaccharide that is soluble in diluted acid solutions [2, 19].
Chitosan has many advantageous properties including biodegradability, high

12

biocompatibility, bioadhesivity to hard and soft tissue, reactive side groups that allow it
to be easily modified, low cost, and high availability [2, 19]. It has also been shown to be
effective as a drug delivery system that can carry antibiotics, release stored drugs over
time at a predictable rate, and degrade efficiently [19, 45]. Polyethylene glycol also has
many valuable, inherent qualities including low immunogenicity and protein resistance
[70] as well as the ability to increase biocompatibility, biodegradability, and antibiotic
elution and activity when blended with chitosan to form sponges [50, 51]. For this body
of work, both acidic chitosan and neutral PEG blended chitosan sponges were fabricated
and combined in various acidic to neutral ratios including 60:40, 50:50, and 40:60.
In order to determine the feasibility of our chitosan/PEG paste (CPP) as a local
drug delivery device for the prevention of bacterial wound infections, we must ask the
following questions about the selected CPP variations: Are they easily injectable with a
syringe, for easy application, and adhesive to tissue, to minimize migration of the device
from the wound site? Do they exhibit in vitro degradability and biocompatibility? Can
they elute common antibiotics used to treat and remain active against bacterial strains in
vitro? Finally, are they effective in preventing the establishment of a biofilm forming
bacterial infection in a functional animal model?
Materials and Methods
Fabrication
All materials were purchased from Fisher Scientific (Pittsburgh, PA) unless
otherwise noted. The chitosan and PEG-modified chitosan products were prepared as
previously reported using chitosan powder (Chitinor AS, Tromsø, Norway) and/or 6,000
g/mol PEG (Sigma Aldrich, St. Louis, MO) [50, 51]. For the neutral portion of the paste,
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PEG was dissolved followed by chitosan in an acetic acid solution. The acidic portion of
the paste and neutral control sponges (used as the control for all experiments, excluding
injectability) were made in a similar manner, without PEG. Chitosan/PEG and chitosan
solutions were cast into 500 mL containers at a volume of 333 mL, frozen overnight at 20°C, and lyophilized to create acidic, dehydrated sponges. Some chitosan sponges were
set aside to form the acidic portion of the paste and 100% acidic chitosan paste (used in
injection and biocompatibility testing), while others for control chitosan sponges along
with all chitosan/PEG sponges were neutralized in NaOH, washed with water until a
neutral pH was reached, and frozen and lyophilized again to create neutral, dehydrated
sponges. The acidic chitosan and neutral chitosan/PEG products were ground separately
into a powder, with flake sizes ≤ 0.5 mm in diameter, using a blade grinder. Three
different combinations of CPP were made by varying the ratios of acidic chitosan to
neutral chitosan/PEG product: 60:40, 50:50, and 40:60 ratios. A 1× phosphate buffered
saline (PBS) in ultrapure water solution at 7.5 times the paste’s dehydrated weight was
added to the dehydrated chitosan powder to produce a hydrated chitosan/PEG paste. All
samples used for biological testing were sterilized with ethylene oxide gas prior to
hydration.
Injection
Injectability was assessed by ejecting the paste from a standard 25 mL repeater
pipette syringe with a modified 3.25 mm diameter tip opening (n = 3). Each syringe was
loaded with 6 mL of paste and fixed into an Instron 33R Universal Testing Machine
model 4465 (Instron, Norwood, MA) with a 5 kN load cell, automated by Instron’s
Bluehill 2 (v2.13) software, which compressed the syringe plunger at 1 mm/sec to fully
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eject the paste. Maximum ejection force was recorded and compared to a clinically
relevant maximum ejection force that an individual could achieve of 330 N [63].
Injectability was also visually assessed by ejecting small quantities (0.5 mL) of paste
from identical modified repeater pipette syringes (n = 5).
Adhesion
To determine the adhesiveness of the paste formulations and control sponges,
porcine cervical vertebrae were used as representative hard and soft tissues (Kroger,
Memphis, TN) and coated in fetal bovine serum (FBS) to simulate blood-like
components. Adhesion was visually assessed by adhering 5 mL of paste or a 22x23 mm
sponge to the FBS coated tissue and timing its adherence for a minimum of 1 minute (n =
3). Each sample was then doused with 10 mL of PBS as simulated wound fluid to
observe if this would dislodge the sample.
Degradation
In vitro degradation was assessed by weight reduction over time based on a
previous method [51]. Dehydrated sample weights were recorded before hydration (n =
5), and each 5 mL hydrated paste sample or 22x23 mm sponge was then placed in a
metal, hemispherical container (Norpro, Everett, WA) with numerous holes
(approximately 1.5 mm in diameter). The container opening was covered with para-film
whilst ensuring that none of the holes were covered. The porous container was placed
inside a plastic container, para-film side down, subsequently submerged in 50 mL of
lysozyme solution, and placed in an incubator on a shaker. Samples were incubated up to
10 days, with samples taken every 2 days and every 6 hours through the first day. The
lysozyme solution was completely replaced at 6 hour intervals. Upon removal, the
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degraded samples were dried in a vacuum oven at 80°C for 48 hours. The dried samples
were weighed and the percent CPP remaining was calculated.
Biocompatibility
In vitro cytocompatibility was assessed using a protocol modified from Parker et
al. [50, 51]. Normal human dermal fibroblast (NHDF) cells (Lonza, Walkersville, MD)
(passages 4 and 5) were seeded at 2.0 x 104 cells/mL in 12-well tissue culture plates in
complete media under standard cell culture conditions. The complete media was
refreshed with 2 mL of fresh media after 24 hours and approximately 0.5 mL of each
paste ratio was injected or a PBS hydrated, 8 mm diameter sponge was lowered into a
cell culture insert with an 8.0 μm pore size membrane, each of which was subsequently
lowered into the media of one well (n = 5). After 24 and 72 hours of incubation, the
inserts containing the samples were removed and the Promega Cell Titer-Glo®
Luminescent Cell Viability assay (Promega, Madison, WI) was used to measure the
luminescent signal, which corresponded to the number of viable cells and amount of
adenosine triphosphate, at 590 nm on a BioTek Synergy H1 plate reader (BioTek,
Winooski, VT). Luminescence values were normalized to TCP controls from each time
point to determine percent cell viability.
Elution
The in vitro concentration release profile of vancomycin was determined over
three days by high performance liquid chromatography (HPLC). Elution utilized the same
setup as degradation, with the exceptions of CPP variations and neutral 1% chitosan
sponges being hydrated with 5 mg/mL vancomycin or amikacin in a 1× PBS solution (n =
5) and utilizing 1× PBS instead of lysozyme solution. Samples to be used for HPLC and
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antibiotic activity were collected at 1, 3, 6, 12, 24, 48, and 72 hours with the 1× PBS
solution completely replaced at every time point. HPLC filtered vials with a 0.45 μm pore
size were used to remove any large chitosan or PEG particles due to degradation in order
to prevent congestion in the column. Vancomycin concentrations were measured utilizing
a reversed-phase C18 column with mobile phase containing 35% acetonitrile and 65%
phosphate buffer at 0.1 M and 3 pH. Vancomycin had a 2.5 minute retention time using a
1.0 mL/min flow rate with a 250 nm UV detection. All eluate concentrations were
normalized to standard curves with known concentrations of vancomycin. Amikacin
samples collected were only utilized for antibiotic activity testing.
Activity
The antibiotic activity of the vancomycin and amikacin eluted from the 60:40,
50:50, and 40:60 paste variations and sponges was determined using zone of inhibition
(ZOI). On trypticase soy broth (TSB) agar plates, blank discs 6 mm in diameter were
placed on a lawn of S. aureus (ATCC 12598) or P. aeruginosa (ATCC 27317) and were
hydrated with 20 μL of vancomycin or amikacin eluate samples, respectively (n = 5). The
TSB agar plates were incubated at 37°C and removed after 24 hours for photography and
measurement of ZOI diameters, not including the discs.
Functional Animal Model
Following an established mouse model protocol [10, 50, 67] approved by the
University of Arkansas for Medical Sciences IACUC (protocol #3608), 24 NIH Swiss
mice were used to assess in vivo prevention of the growth of biofilm forming S. aureus
by vancomycin loaded CPP and chitosan sponges. The 50:50 and 40:60 CPP as well as
the neutral 1% chitosan sponges were each hydrated with either 4 mg/mL vancomycin in
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a 1× PBS solution or PBS alone, resulting in six test groups with four animals each (two
sites per mouse). After implantation of a 1 cm long catheter subcutaneously, 0.25 mL of
paste was injected using a U-100 insulin syringe (BD, Franklin Lakes, NJ) with the
needle removed or an 8 mm diameter sponge was placed adjacent to each catheter (n =
8). After closure, 1 cc of 104 colony forming units (CFUs) of biofilm forming S. aureus
(UAMS-1 strain) was injected into the lumen of each catheter. The mice were sacrificed
48 hours after surgery, where catheters were retrieved, sonicated in PBS to remove
adherent bacteria, and resultant diluted aliquots were plated on TSB agar overnight in a
37°C incubator in order to count the number of bacteria recovered in each catheter.
Statistical Analysis
In vitro degradation, biocompatibility, and antibiotic elution and activity were
analyzed using two-way Analysis of Variance (ANOVA) followed by Holm-Sidak post
hoc tests. Injectability with the Instron and remaining colony forming units from the in
vivo mouse infected catheter model were analyzed using Kruskal-Wallis one-way
ANOVA on ranks followed by Tukey post hoc tests. All results, excluding the percent
clearance of bacteria from catheters in the mouse model, are presented as the average ±
the standard deviation. SigmaPlot 12.5 (Systat Software Inc, San Jose, CA) was used for
analysis, and evidence of a statistically significant difference occurred when p < 0.05.
Results
Previous evaluations were conducted over a wide range of chitosan/PEG paste
(CPP) ratios in order to determine the smaller range of ratios that was used in this focused
study. Chitosan/PEG paste ratios utilized were 70:30, 50:50, and 30:70 to evaluate
degradation, biocompatibility, and injectability. The degradation results showed that all
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three paste formulations would degrade over time, with an increase in degradation and
acidic product being directly correlated. The paste biocompatibility results showed that
the 70:30 CPP was the least biocompatible and that the 50:50 and 30:70 versions
exhibited similar, high biocompatibility to the control neutral sponges after 24 and 72
hours. While the 30:70 paste had high cell viability, it proved to not be injectable from a
syringe, reaching a maximum ejection force of 382 N, which was well over the clinically
relevant maximum ejection force that an individual could achieve of 330 N [63]. Based
on these screening results, the 60:40, 50:50, and 40:60 CPP variations were selected for
the further assessments presented.
Injectability and Adhesivity
Initially, a significant difference was thought to occur among the ejection forces
for the three paste variations and the air ejected from the empty control tube (p = 0.043);
however, the post hoc test revealed there were none present (Fig. 1). In addition, all
ejection forces were less than the cutoff of 330 N [63], and all paste ratios were easily
injectable with a handheld repeater pipette. The 60:40, 50:50, and 40:60 ratios, along
with the sponges, adhered to the FBS coated tissue for a minimum of 1 minute (Fig. 2AD). Conversely, the 100% acidic chitosan paste started migrating from the tissue
placement site immediately (Fig. 2E), and one of the three sponge samples was
completely removed when doused with PBS (Fig. 2F).
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60:40 CPP
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50:50 CPP
40:60 CPP
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Air
150
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0
CPP Type

Fig. 1 Ejection results represented as the average ± standard deviation of force required
to eject air and 60:40, 50:50, and 40:60 chitosan/PEG paste variations from a syringe
(n = 3).

A

B

C

D

E

F

Fig. 2A-F (A) 60:40, (B) 50:50, and (C) 40:60 chitosan/PEG pastes, (D) neutral 1%
chitosan sponge, and (E) 100% acidic chitosan paste adhering to FBS coated porcine
cervical vertebrae and (F) 40:60 chitosan/PEG paste being doused with 10 mL of PBS.
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In Vitro Degradation and Biocompatibility
After undergoing lysozyme mass based degradation, all sample variations
exhibited a significant decrease in the percentage of paste or sponge remaining through
day 10 (p < 0.001), which slightly slowed for the 60:40, 50:50, and 40:60 between days 4
and 6 (p = 0.768), days 4 and 8 (p = 0.192), and days 2 and 8 (p = 0.586), respectively
(Fig. 3). After 2 days, all paste variations had degraded to a similar point (p > 0.05), but
those with higher acidic percentages demonstrated increased degradation thereafter over
those with lower acidic portions (p ≤ 0.024). The neutral chitosan sponges decreased in
weight through 24 hours (p = 0.005) then continued to gain weight through day 10, where
the 60:40, 50:50, and 40:60 CPP variations displayed a significantly lower percent
remaining, 97.74, 92.94, and 80.58% respectively, compared to the neutral control
sponge (p ≤ 0.001).
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Fig. 3 In vitro enzymatic degradation reported as the average ± standard deviation of
weight percent remaining of the sample for 60:40, 50:50, and 40:60 chitosan/PEG paste
variations and neutral 1% chitosan sponges over 10 days (n = 5). (* represents p < 0.05
versus itself at all time points except § for all pastes at day 2 and 40:60 and 50:50 at day
1, † represents p < 0.05 showing significant degradation through marked time points)

After NHDF exposure to paste and sponges for 1 and 3 days, the 60:40 CPP had
significantly lower cell viability at both time points than all other samples (p ≤ 0.006),
excluding the 100% acidic paste (p < 0.001; positive control) (Fig. 4). The 40:60 CPP
was the only variation similar to the untreated cells after 24 hours (p = 0.219), but
exhibited significantly lower viability, along with all other samples, than the TCP control
after 72 hours (p ≤ 0.015). While the 50:50 CPP showed lower viability than the 40:60
CPP and neutral sponge (negative control) after 24 hours (p ≤ 0.025), these three samples
all displayed similar viability after 72 hours (p ≥ 0.800). Upon microscopic examination,
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there was no cellular malformation, sloughing, or lysis for any samples except the 100%
acidic paste, but there was an increase in degradation particles present for the 60:40 and
50:50 CPP variations.
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Percent Cell Viability (%)
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†
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*

100% Acidic CP
60:40 CPP

60

50:50 CPP
40

40:60 CPP

*

Neutral 1% CS

*
20
0
24

72
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Fig. 4 In vitro direct contact biocompatibility normalized to tissue culture plastic control
reported as the average ± standard deviation of percent cell viability for 100% acidic
chitosan paste, 60:40, 50:50, and 40:60 chitosan/PEG paste variations, and neutral 1%
chitosan sponges after 24 and 72 hours (n = 5). (* represents p < 0.05 versus all at
respective time point, † represents p < 0.05 versus 40:60 CPP and Neutral 1% CS at
respective time point)

In Vitro Antibiotic Elution and Antibacterial Activity
All paste variations released steady concentrations of vancomycin over 72 hours
of in vitro elution, with the 60:40, 50:50, and 40:60 CPP releasing 29.28, 32.03, and
35.21% of the original amount of antibiotics loaded, respectively, leaving 64.79-70.72%
of the original concentration of antibiotic to be released over time (Fig. 5A). The neutral
control sponges released an initial, high burst of 10.61% of the loaded vancomycin, but
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only released a total of 13.32% vancomycin through 6 hours with very minimal release
thereafter. Vancomycin concentrations released from the CPP variations remained above
the minimal inhibitory concentration (MIC) for S. aureus through 72 hours while the
neutral control sponge failed to release concentrations above the MIC after 6 hours (Fig.
5B). The percent vancomycin released from the CPP was significantly lower after 6 hours
(p ≤ 0.001), but concentrations increased as degradation increased through 48 hours and
was again significantly lower at 72 hours (p ≤ 0.001).
The vancomycin and amikacin eluates from the paste remained active through 72
hours and 24 hours, respectively, while the eluates from the sponges only remained active
through 6 and 3 hours against S. aureus and P. auruginosa, respectively (Table 1A-B).
For the vancomycin eluates, the control sponge exhibited a similar ZOI diameter to the
40:60 CPP at 1 hour (p = 0.252) but was significantly smaller than all CPP variations at
all other time points (p ≤ 0.001). Although all CPP exhibited a significantly lower
diameter at 72 hours (p ≤ 0.001), they still effectively inhibited S. aureus. For the
amikacin eluates, the control sponge also displayed a similar diameter to all CPP at 1
hour (p ≥ 0.288), and all samples exhibited a significantly lower diameter at 48 and 72
hours (p ≤ 0.001), with only the 60:40 remaining active against P. auruginosa through 48
hours.
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10
8
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*
*

4

*

*

2
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6

12
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24

60:40 CPP

50:50 CPP

Neutral 1% CS

S. aureus MIC

48
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40:60 CPP

Fig. 5A-B In vitro release of vancomycin from 60:40, 50:50, and 40:60 chitosan/PEG
paste variations and neutral 1% chitosan sponges over 72 hours reported as the average ±
standard deviation in (A) Cumulative percent vancomycin released and (B) percent
vancomycin released at each time point (n = 5). (* represents p < 0.05 vs hour 1,
** represents p < 0.05 vs all other time points)
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Table 1A-B Zone of inhibition antibacterial activity results reported as the average ±
standard deviation of the inhibited growth diameter using (A) vancomycin antibiotic
eluates against S. aureus and (B) amikacin antibiotic eluates against P. auruginosa from
60:40, 50:50, and 40:60 chitosan/PEG paste variations and neutral 1% chitosan sponges
after 24 hours of direct contact (n = 5). (* represents p < 0.05 vs hour 1, ** represents
p < 0.05 vs all other time points)
S. aureus Zone of Inhibition Diameter (mm), n = 5

A
Sample
Groups
60:40 CPP
50:50 CPP
40:60 CPP
Neut 1%
CS

Vancomycin Eluate Sampling Time Points (hours)
1
13.6 ±
1.1
13.6 ±
0.5
12.8 ±
0.4
12.0 ±
0.7**

3
11.6 ±
0.5*
13.2 ±
1.1
11.8 ±
1.1
7.1 ±
0.5

6
10.2 ±
0.4*
11.0 ±
0.0*
11.75 ±
0.5
1.4 ±
3.1

12
12.2 ±
0.4
12.2 ±
0.4
11.6 ±
0.5

24
12.2 ±
0.4
11.8 ±
0.4*
11.6 ±
0.5

48
12.6 ±
0.5
13.8 ±
0.4
12.0 ±
0.0

72 *
10.8 ±
0.8
10.2 ±
0.8
8.4 ±
0.9

0

0

0

0

P. auruginosa Zone of Inhibition Diameter (mm), n = 5

B
Sample
Groups
60:40 CPP
50:50 CPP
40:60 CPP
Neut 1%
CS

Amikacin Eluate Sampling Time Points (hours)
1
10.4 ±
0.9
13.6 ±
2.2
11.4 ±
1.6
10.8 ±
1.9**

3
9.0 ±
2.3
10.6 ±
2.1
9.2 ±
1.3
5.8 ±
3.2

6
10.2 ±
2.2
9.6 ±
1.1*
8.0 ±
0.7*

12
8.4 ±
1.5
5.8 ±
3.2*
9.2 ±
1.6

24
8.8 ±
1.8
4.2 ±
3.8*
5.8 ±
3.2*

48*
2.8 ±
3.8

72*

0

0

0

0

0

0

0

0

0

0

In Vivo Bacterial Prevention and Clearance
Both variations of chitosan/PEG paste and neutral chitosan sponges proved
effective in preventing S. aureus from contaminating the implanted catheters. The
vancomycin loaded 50:50 and 40:60 CPP variations resulted in a 100% clearance rate of
catheters, while the vancomycin loaded sponges cleared bacteria from seven of the eight
catheters (Fig. 6A). Additionally, all vancomycin loaded implants displayed significantly
less viable CFUs remaining on the catheters than those loaded with PBS only (p < 0.001)
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(Fig. 6B). Furthermore, no signs of redness, significant edema, induration, or suppuration
were visible to indicate a tissue inflammatory response in the mice to the CPP.

Percent of Catheters Cleared (%)
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50:50 CPP, 50:50 CPP, 40:60 CPP, 40:60 CPP, Neutral 1% Neutral 1%
PBS
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Average Colony Forming Units (CFUs)
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Fig. 6A-B (A) Percentage of catheters cleared and (B) average S. aureus colony forming
units per catheter for those retrieved from mice treated with 50:50 and 40:60
chitosan/PEG paste variations and neutral 1% chitosan sponges over 48 hours (n = 8, 2
catheters per mouse). All samples were loaded with either PBS alone or 4 mg/mL of
vancomycin. (* represents p < 0.05 vs all vancomycin samples)
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Discussion
Complex musculoskeletal wound infections, especially those complicated with
biofilm forming bacterial strains, often result in increased treatment time, number of
surgeries, costs, and patient morbidity [7, 13, 20, 24]. Efficacy of systemic antibiotic
therapy is substantially reduced at avascular musculoskeletal wound sites, and can only
help clear localized bacteria at increased, potentially adverse effect-causing, dosages [29,
55]. The clinical need for a local drug delivery device that is efficient in clearing bacteria,
is biocompatible and completely biodegradable, and can be loaded with tailored
antibiotics at point-of-care resulted in the development of chitosan sponges [46, 49-51,
58]. In addition, a chitosan paste from these sponges was developed [57] due to a need
for minimal migration of the device from the wound site and improved wound coverage
[34, 58]. Furthermore, the chitosan paste maintains qualities desired by surgeons such as
degradability, biocompatibility, and antibiotic activity characteristics. Our research
questioned whether modifying the chitosan paste with PEG would result in a viable, local
antibiotic delivery device that will satisfy the discussed clinical needs.
Limitations in this study include the small size of the mice used in the functional
animal model, where a larger animal would present a defect more representative of a
large, complex, and infected musculoskeletal wound in a clinical setting. Although the
paste loaded with vancomycin proved effective in preventing bacterial infection in mice,
treatment of an established bacterial infection should be assessed in future studies. The
chitosan/PEG paste showed desirable degradation properties and much improvement for
in vitro biocompatibility over the more acidic paste, but extended in vivo testing is
needed for confirmation. Excluding biocompatibility and the in vivo mouse model, all

28

paste samples used were non-sterile. Some property changes, including the injectability
of the 40:60 paste, were observed for gamma radiation sterilized samples during
biocompatibility testing. This led to changing the sterilization method from gamma
irradiation to ethylene oxide, which presented minimal property changes. Additionally, a
new syringe with a smaller diameter was employed for biological testing to improve
injectability of the paste. Follow-up expanded in vitro characterization of sterilization
method-induced changes should be pursued. The data presented, despite its limitations,
suggests that the chitosan/PEG paste has the potential to prevent and treat polymicrobial
infections in complex musculoskeletal injuries.
Few reported studies were found with a similar design and purpose to the
chitosan/PEG paste device investigated in this work. Wu et al. investigated a sprayable,
thermosensitive chitosan/PEG hydrogel for nasal drug delivery [68], Lih et al. developed
an injectable chitosan-PEG-tyramine hydrogel to be used as tissue adhesives for wound
healing [37], and Bhattarai et al. and Jiang et al. explored injectable PEG-graftedchitosan thermosensitive hydrogels for sustained protein release and drug delivery,
respectively [12, 33]. Of the studies found, none explicitly examined injectability;
however, all devices were characterized as in situ forming hydrogels injectable from a
needle while our composite paste is injected out of a larger cannula device. Lih et al. also
found that their chitosan-PEG-tyramine hydrogel was able to remain adhesive to porcine
skins just as our chitosan/PEG paste was able to remain adhesive to porcine vertebral
tissue [37].
The literature on the biocompatibility of chitosan/PEG hydrogels, while abundant,
is limited regarding the degradation properties of this combination. Parker et al.
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developed a neutral chitosan/PEG sponge for drug delivery also utilizing 6,000 g/mol
PEG and reported 55-75% sponge remaining after 10 days of lysozyme mass based
degradation, which experienced significantly lower degradation than our chitosan/PEG
paste device with 0-24% paste remaining [51]. Parker et al. also reported 99-100% of
their neutral chitosan sponge remaining, which is comparable to our neutral chitosan
sponge with 100-102% remaining after 10 days [51]. In vivo degradation was also
assessed by Parker et al., with 15-25% and 5-15% sponge remaining in the chitosan/PEG
and neutral chitosan sponges, respectively, after 10 days of implantation in a rat
intramuscular model [51]. De Souza et al., who developed an injectable, chitosanphospholipid blended with lauric chloride or lauric aldehyde to aide in localized
therapeutic applications, also evaluated in vivo degradation in an intraperitoneally
injected mouse model and found their chitosan-blend degradable with 7.5% remaining
after 4 weeks [21]. Based on these results and the rapid in vitro degradation experienced
by our chitosan/PEG paste, we can project that our paste has the potential to degrade
completely in an in vivo environment.
The literature on in vitro biocompatibility of chitosan/PEG hydrogels is
consistent, but results are more variable for in vivo models. In previous in vitro studies,
multiple chitosan/PEG hydrogels were reported to be biocompatible without eliciting
significant cytotoxicity [33, 66, 68] along with various chitosan hydrogels [21, 61] and
chitosan/PEG sponges [50, 51]. However, results vary more for in vivo studies, with
reports ranging from no inflammatory tissue present after contact with various hydrogels
[21, 37, 68], to moderate inflammatory responses in Sprague-Dawley rats from some
chitosan/PEG devices [33, 51], to immediate inflammation and tissue encapsulation
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around an implanted chitosan-glycerophosphate hydrogel [59]. The chitosan/PEG paste
developed elicited similar cell viability to the control neutral chitosan sponge, which is
comparable to the in vitro studies mentioned. Based on previously reported in vivo
biocompatibility for other chitosan/PEG devices, it is expected that the paste would elicit
a minimal to moderate inflammatory response in a small animal model.
Other chitosan/PEG hydrogels were successful in delivering a steady release of
bovine serum albumin for 70 hours [12] and 90 hours [66] and cyclosporin A for 3 weeks
[33]; however, none of them tested the in vitro release or activity of antibiotics. Parker et
al. reported an initial burst release of 16% and 7% loaded vancomycin from neutral
chitosan/PEG and chitosan sponges after 1 hour, respectively, with a significant decrease
in eluted antibiotic thereafter [50]. Noel et al. also investigated the in vitro release
properties of vancomycin from chitosan sponges made with lactic and acetic acid, and
reported an initial burst release of 20% loaded vancomycin after 1 hour, respectively,
while also experiencing a significant decrease in eluted antibiotic thereafter [46]. Our
chitosan/PEG paste and neutral chitosan sponges experienced an initial burst release of 58% and 11% loaded vancomycin after 1 hour, respectively, with a steady antibiotic
release through 72 hours from the paste and severely decreased levels thereafter for the
sponges. Noel et al. found that 98% of the loaded vancomycin was released after 72
hours [46]; however, our chitosan/PEG paste only eluted 29-35% of the total
vancomycin, which is more conducive to a longer local drug delivery. While vancomycin
concentrations found by Parker et al. were above the MIC through 24 hours, eluates
utilized for turbidity testing only remained active against S. aureus through 6 hours [50].
Unlike the sponges reported by Parker et al., Noel et al. found that the levels of
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vancomycin eluted remained above the MIC and eluates remained active through 72
hours [46], which is similar to our findings with the chitosan/PEG paste. Noel et al. also
reported amikacin eluates from chitosan sponges remaining active through 48 hours [46]
while amikacin eluates from our chitosan/PEG paste only remained active through 24
hours.
Again, other chitosan/PEG hydrogels were successful in in vivo delivery of
insulin to decrease blood glucose in mice [68] and cyclosporin A at effective levels in
rats for 5 weeks [33], but none of them tested the in vivo activity of antibiotics. Using the
neutral control sponge, we found 87.5% of catheters were completely cleared of bacteria
while Parker et al. only reported a 50% clearance rate; however, the number of remaining
viable CFUs in both studies was nominal [50]. Parker et al. reported higher bacterial
counts for samples loaded with only PBS as compared to the chitosan/PEG paste tested,
but similarly found no remaining viable colony forming units in any catheters exposed to
the chitosan/PEG sponge utilizing 6,000 g/mol PEG loaded with vancomycin [50].
The investigated chitosan/PEG paste is a composite unlike other chitosan/PEG
hydrogels that form in situ and must be injected through a larger cannula device instead
of a needle. The paste is also adhesive to both hard and soft tissue, more readily
degradable, and displays similar cytocompatibilty when compared to other chitosan and
chitosan/PEG drug delivery devices found. The chitosan/PEG paste also demonstrated a
more desirable antibiotic elution profile than other similar devices by providing an
extended drug release that will remain active over longer periods of time. The CPP also
proved as effective as its predecessor in preventing bacterial contamination in a murine
catheter model. In conclusion, chitosan paste modified with polyethylene glycol is an
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easily injectable, bioadhesive, readily biodegradable, and biocompatible material with the
potential to provide point-of-care antibiotic loading and active antibiotics release locally
to inhibit in vitro bacterial growth and prevent in vivo bacterial contamination.
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CHAPTER 4
CONCLUSIONS

For the studies presented in this body of work, chitosan paste modified with
polyethylene glycol (PEG) was developed as a potentially biocompatible and completely
degradable local antibiotic delivery system whose drug release can be tailored to
individual patient need and surgeon preference and is injectable for ease of use, adhesive
to minimize wound migration, and conformable to provide superior wound coverage in
order to increase antibiotic levels directly to the injured wound site and provide a more
effective remedy for musculoskeletal infection control. Material characterization and
functionality of the chitosan/PEG paste were evaluated using in vitro and in vivo methods
to determine the effects of incorporating PEG into the chitosan paste composition.
Some property changes, including the injectability of the 40:60 paste, were
observed for gamma radiation sterilized samples during biocompatibility testing. This led
to changing the sterilization method from gamma irradiation to ethylene oxide, which
presented minimal property changes.
By blending PEG into the chitosan paste formulation, the paste remained adhesive
to both hard and soft tissue and injectable through a syringe. Injectability decreased in
gamma irradiated 40:60 paste, leading to exploration of ethylene oxide sterilization,
which presented minimal property changes. Furthermore, a new syringe with a smaller
diameter was employed for biological testing to improve injectability of the paste. In
vitro degradation was decreased compared to the chitosan paste and increased compared
to the neutral control sponge, which resulted in an improved antibiotic release profile
with active vancomycin concentrations eluted throughout. While vancomycin
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concentrations remained above the MIC for S. aureus for 72 hours, the chitosan/PEG
paste was not as effective in releasing amikacin for which concentrations only remained
above the MIC for P. aeruginosa for 24 hours. The addition of PEG also increased the in
vitro biocompatibility of the 50:50 and 40:60 paste variations over the unmodified
chitosan paste and elicited similar cell viability to the unmodified, neutral chitosan
sponges tested as the negative control. The 50:50 and 40:60 chitosan/PEG paste
variations also displayed improved bacterial contamination prevention in vivo over the
unmodified paste and sponges by clearing bacteria from 100% of S. aureus infected
catheters implanted in the mouse model. These experimental results indicate that the
50:50 and 40:60 chitosan/PEG paste variations both possess the potential to be used as an
effective local drug delivery device to aid in bacterial wound infection prevention;
however, it is recommended to continue future testing with the 50:50 paste due to its
increased degradation profile, extended antibiotic release, and enhanced eluate activity
over the 40:60 paste.
In conclusion, the results presented in this body of work provide confirmation of
the stated hypothesis: that modifying chitosan paste with polyethylene glycol will
improve the biocompatibility and biodegradability of this local delivery system while
maintaining its adhesiveness to minimize implant migration, injectability for ease of use,
and capability of point-of-care loading of various antibiotics to remain active against and
prevent the establishment of bacterial infections in musculoskeletal injuries. Although an
in vivo model is still needed to confirm degradation and biocompatibility of the 50:50
chitosan/PEG paste, the significant in vitro degradation experienced indicates the
potential for eventual, complete degradation and the similar percent in vitro cell viability
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to the unmodified chitosan sponges experienced indicates the potential to produce a
minimal to mild tissue inflammatory response. With additional research, the 50:50
chitosan/PEG paste variation has the potential to create a local antibiotic delivery system
with the ability to reliably provide adjunctive infection prevention therapy in conjunction
with standard surgical treatment of musculoskeletal injuries.
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CHAPTER 5
FUTURE WORK

In order to completely evaluate the properties of the chitosan/PEG paste, further
in vitro and in vivo research must be done. Additional in vitro work needed includes
injection, adhesion, degradation, and antibiotic elution and activity using ethylene oxide
sterilized paste products because sterilization has shown to decrease injectability and
increase degradation, meaning other properties could be affected as well. Injectability
specifically needs to be addressed; a new type of syringe better suited to the paste’s
material properties needs to be used or developed in order to be easily used.
While the paste did not elicit a noticeable immune response when implanted in
the mice, it still needs to be tested in a functional animal model for biocompatibility and
degradation. Our lab has previously tested the chitosan paste in a rat subcutaneous model
with only soft tissue damage, so a rat tibial defect model would be beneficial in
determining the inflammatory response, degradation, and device migration of the paste
when bone and soft tissue damage are both present. A mouse infected catheter model was
tested in this work to simulate a polymer implant, but a mouse infected pin model with
metal hardware would also be beneficial in determining how the paste responds to
metallic implants with an infection present. While the paste proved effective in clearing
the infection in the mice, only prevention of a bacterial infection was tested; treatment of
an established bacterial infection should also be assessed in future studies. The addition
of PEG also allows for hydrophobic antifungals and biofilm dispersants to be loaded into
the paste [18, 32, 41, 42, 50, 51, 64]; therefore, additional in vitro and in vivo work for
these agents would be advantageous in treating fungal and antibiotic resistant infections.
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Other future work is to include expanding upon the 50:50 chitosan/PEG paste
variation by trying to formulate a completely acidic, once lyophilized paste by varying
concentrations of chitosan, 8,000 g/mol PEG, and acetic acid, based on the 0.5% chitosan
blended with 0.5% 8,000 g/mol PEG sponge formulation developed by Parker et al.
which proved to be biocompatible, biodegradable, and readily active against bacteria and
fungi when loaded with antibiotics and/or anti-fungals [50, 51].
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APPENDIX A: DETAILED MATERIALS AND METHODS FOR CHAPTER 3
Fabrication
All materials were purchased from Fisher Scientific (Pittsburgh, PA) unless
otherwise noted. The chitosan/PEG paste was fabricated using Chitopharm S chitosan
powder (Chitinor AS, Tromsø, Norway) with an 82.46 ± 1.679 degree of deacetylation
and an average molecular weight of 250.6 kDA and/or polyethylene glycol with a
molecular weight of 6,000 g/mol (PEG; Sigma Aldrich, St. Louis, MO). For the neutral
portion of the paste, 0.5% w/v of PEG was dissolved in a 1% v/v acetic acid in ultrapure
water solution, and following dissolution, 0.5% w/v of chitosan was dissolved in the
same solution. The acidic portion of the paste and neutral control sponges (used as the
control for all experiments, excluding injectability) were made in the same manner, but
dissolving only 1 % w/v of chitosan in the acetic acid solution. Chitosan/PEG and
chitosan solutions were cast into 500 mL containers at a volume of 333 mL, frozen
overnight at -20 °C, and lyophilized in a benchtop freeze dryer (LabConco, Kansas City,
MO) to create acidic, dehydrated sponges. The chitosan/PEG and control chitosan
sponges were neutralized in 0.25 M or 0.6 M sodium hydroxide (NaOH), respectively,
and washed with ultrapure water until a neutral pH was reached, frozen at -20 °C for one
hour, and lyophilized again to create neutral, dehydrated sponges. The remaining acidic
chitosan sponges were not neutralized and only lyophilized once to form the acidic
portion of the paste and 100% acidic chitosan paste (used in injection and
biocompatibility testing). The acidic 1% chitosan and neutral 1% chitosan/PEG products
were ground separately into a powder, with flake sizes ≤ 0.5 mm in diameter, using a
blade grinder. Three different combinations of chitosan/PEG paste (CPP) were made by
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varying the ratios of acidic chitosan to neutral chitosan/PEG product: 60:40, 50:50, and
40:60 ratios. A 1× phosphate buffered saline (PBS) in ultrapure water solution at 7.5
times the paste’s dehydrated weight was added to the dehydrated chitosan powder in
order to make it a hydrated chitosan/PEG paste. All samples used for biological testing
were sterilized with ethylene oxide gas prior to hydration.
Injection
Injectability of the CPP variations was assessed by ejecting the paste from a
standard 25 mL Eppendorf repeater pipette syringe with a modified 3.25 mm diameter tip
opening (n = 3). Each syringe was loaded with 6 mL of paste and fixed into an Instron
33R Universal Testing Machine model 4465 (Instron, Norwood, MA) with a 5 kN load
cell, automated by Instron’s Bluehill 2 (v2.13) software, which compressed the syringe
plunger at 1 mm/sec to fully eject the chitosan/PEG paste from the syringe. Maximum
ejection force was recorded and compared to a clinically relevant maximum ejection
force that an individual could achieve of 330 N [63]. Injectability was also visually
assessed by ejecting small quantities (0.5 mL) of paste from identical modified repeater
pipette syringes using an Eppendorf repeater pipette (n = 5).
Adhesion
To determine the adhesiveness of the paste variations and sponges, porcine
cervical vertebrae were used as representative hard and soft tissues (Kroger, Memphis,
TN) and coated in fetal bovine serum (FBS) to simulate blood-like components.
Adhesion was visually assessed by adhering 5 mL of each variation of paste or a 22x23
mm sponge to the FBS coated tissue and timing its adherence for a minimum of 1 minute
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(n = 3). Each sample was then doused with 10 mL of PBS as simulated wound fluid to
observe if this would dislodge the sample.
Degradation
In vitro degradation was assessed by weight reduction of the CPP variations and
neutral 1% chitosan sponges over time. Dehydrated weights of each sample for each time
point were recorded before being hydrated (n = 5). Each 5 mL hydrated paste sample or
22x23 mm sponge was then placed in a metal, hemispherical container (Norpro, Everett,
WA) with numerous holes (approximately 1.5 mm in diameter). The container opening
was covered with para-film whilst ensuring that none of the holes were covered. The
porous container was placed inside a 125 mL plastic container, para-film side down, and
subsequently filled with 50 mL of a 1 mg/mL chicken egg white lysozyme in ultrapure
water solution in order to completely cover the sample. Once the lids of the plastic
containers were secure, samples were placed in an incubator at 37 °C on a shaker.
Samples remained within the incubator for 10 days, with time points taken every 2 days
and every 6 hours through the first day, and the lysozyme solution being completely
replaced at 6 hour intervals throughout. Once removed from the incubator, the degraded
samples were transferred to an aluminum dish and placed in a vacuum oven at 80 °C for
48 hours to dry. The dried samples were then weighed, and the percent CPP remaining
was calculated by dividing this dry, degraded weight by the initial, dehydrated weight
and multiplying by 100. Because the drying process was destructive to the samples, new
samples were used at each time point.
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Biocompatibility
In vitro biocompatibility was assessed by determining the cell viability of normal
human dermal fibroblast (NHDF) cells (Lonza, Walkersville, MD) after being in contact
with the 60:40, 50:50, and 40:60 CPP variations as well as neutral 1% chitosan sponges
and fully acidic 1% chitosan paste as negative and positive controls, respectively. Cells
(passages 4 and 5) were seeded at 2.0 x 104 cells/mL and allowed to proliferate on 12well transparent tissue culture plates in complete media. The complete media per well
consisted of 2 mL High Glucose Dulbecco’s Modified Eagle Medium (DMEM) with
10% FBS and 1% antibiotics/antimycotics consisting of penicillin, streptomycin, and
amphotericin B. All of this was done under standard cell culture conditions at 37 °C and
5% CO2 atmosphere. The complete media was refreshed after 24 hours and
approximately 0.5 mL of each paste ratio was injected or an 8 mm diameter sponge was
lowered into a cell culture insert with an 8.0 μm pore size membrane, each of which was
subsequently lowered into the media of one well (n = 5). Untreated NHDF cells on tissue
culture plastic (TCP) were considered to be at 100% cell viability. The 1% chitosan
sponges were hydrated in warmed PBS for approximately 20 minutes before being placed
into the inserts. After the plates were incubated for 24 and 72 hours, the inserts
containing the samples were removed and the Promega Cell Titer-Glo® Luminescent
Cell Viability assay (Promega, Madison, WI) was used to measure the luminescent
signal, which corresponded to the number of viable cells and amount of adenosine
triphosphate, at 590 nm on a BioTek Synergy H1 plate reader (BioTek, Winooski, VT).
Luminescence values were normalized to TCP controls from each time point to determine
percent cell viability.
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Elution
The in vitro concentration release profile of vancomycin was determined over
three days by high liquid performance chromatography (HPLC). The CPP variations and
neutral 1% chitosan sponges were hydrated with 5 mg/mL vancomycin in a 1× PBS
solution, and the 5 mL paste or 22x23 mm sponge samples were then placed in a metal,
hemispherical container with numerous holes (n = 5). The container opening was covered
with para-film and placed inside a 125 mL plastic container, para-film side down, and
subsequently filled with 50 mL of 1× PBS and placed in an incubator at 37 °C on a
shaker. Samples to be used for HPLC and antibiotic activity were collected at 1, 3, 6, 12,
24, 48, and 72 hours with the 1× PBS solution completely replaced at every time point.
Vancomycin concentrations were measured utilizing a reversed-phase C18
column with mobile phase containing 35% acetonitrile and 65% phosphate buffer at 0.1
M and 3 pH. Vancomycin had a 2.5 minute retention time using a 1.0 mL/min flow rate
with a 250 nm UV detection. HPLC filtered vials with a 0.45 μm pore size were used to
remove any large chitosan or PEG particles due to degradation in order to prevent
congestion in the column. All eluate concentrations were normalized to standard curves
with known concentrations of vancomycin.
Activity
The antibiotic activity of the vancomycin and amikacin eluted in vitro from the
60:40, 50:50, and 40:60 paste variations and sponges was determined using zone of
inhibition (ZOI). On trypticase soy broth (TSB) agar plates, blank discs 6 mm in diameter
were placed on a lawn of S. aureus (ATCC 12598) or P. aeruginosa (ATCC 27317) and
were hydrated with 20 μL of vancomycin or amikacin eluate samples, respectively (n =
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5). The TSB agar plates were incubated at 37 °C and removed after 24 hours where
pictures were taken and ZOI diameters, not including the discs, were measured.
Functional Animal Model
Following an established mouse model protocol [10, 67] approved by the
University of Arkansas for Medical Sciences IACUC (protocol #3608), 24 NIH Swiss
mice were used to assess in vivo prevention of the growth of biofilm forming S. aureus
by vancomycin loaded CPP and chitosan sponges. Anesthesia was administered to the
mice via isoflurane in an environmental chamber. The backs of the mice were shaved and
a 0.3 cm incision was made in both flanks of each mouse where a 1 cm segment of
polytetrafluoroethylene (PTFE) catheter was implanted subcutaneously (two sites per
mouse). The 50:50 and 40:60 CPP as well as the neutral 1% chitosan sponges were each
hydrated with either 4 mg/mL vancomycin in a 1× PBS solution or PBS alone, resulting
in six test groups with four animals each. Using a U-100 insulin syringe (BD, Franklin
Lakes, NJ) with the needle removed, 0.25 mL of paste was injected or an 8 mm diameter
sponge was placed adjacent to each catheter (n = 8). After the incisions were closed with
surgical glue, 1 cc of 104 colony forming units (CFUs) of biofilm forming S. aureus
(UAMS-1 strain) was injected into the lumen of each catheter. The mice were sacrificed
48 hours after surgery, and the catheters were removed and stored in a sterile saline
solution. The explanted catheters were sonicated in PBS to remove adherent bacteria and
resultant diluted aliquots were plated on TSB agar overnight in a 37 °C incubator in order
to count the number of bacteria recovered from each catheter.
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APPENDIX B: ZONE OF INHIBITION PHOTOGRAPHS
Vancomycin

Fig. 7 Zone of inhibition photographs for vancomycin loaded chitosan/PEG paste and
neutral chitosan sponges over 72 hours (n = 5).
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Amikacin

Fig. 8 Zone of inhibition photographs for amikacin loaded chitosan/PEG paste and
neutral chitosan sponges over 72 hours (n = 5).
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APPENDIX C: PRELIMINARY CHITOSAN/PEG PASTE REFINEMENT DATA
Objective
The goal of these experiments was to evaluate degradation, biocompatibility, and
injectability over a wide range of acidic chitosan to neutral chitosan/PEG product ratios
in order to narrow the range of functional paste variations for further testing.
Materials and Methods
Detailed materials and methods for fabrication and degradation, biocompatibility,
and injection testing of chitosan/PEG paste and chitosan sponges can be found in
Appendix A.
Fabrication
The acidic 1% chitosan and neutral 1% chitosan/PEG products were ground
separately into a powder, and combined into three different acidic to neutral ratios:
70:30, 50:50, and 30:70 ratios. A 1× phosphate buffered saline (PBS) in ultrapure water
solution at 7.5 times the paste’s dehydrated weight was added to the dehydrated chitosan
powder to form a hydrated chitosan/PEG paste (CPP). Paste was not sterilized for testing,
but the neutral control chitosan sponges were using gamma irradiation.
Initial Degradation
Preliminary in vitro degradation was assessed by enzymatic weight reduction of
the 70:30, 50:50, and 30:70 CPP variations over time (n = 3). Samples remained within
the incubator for 1 through 6 day time points with the lysozyme solution being
completely replaced at 24 hour intervals for the longer time points. The percent CPP
remaining was calculated by dividing this dry, degraded weight by the initial, dehydrated
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weight and multiplying by 100. Because the drying process was destructive to the
samples, new samples were used at each time point.
Initial Biocompatibility
In vitro biocompatibility was assessed by determining the cell viability of normal
human dermal fibroblast (NHDF) cells after being in contact with the 70:30, 50:50, and
30:70 CPP variations as well as neutral 1% chitosan sponges (n = 5). Cells (passage 4)
were seeded at 1.21 x 104 cells/mL and allowed to proliferate for 24 hours before inserts
containing the samples were placed in the wells. After 24 and 72 hours of incubation, the
inserts were removed and the Cell Titer-Glo® Luminescent assay was used to measure
the luminescent signal at 590 nm with a plate reader. Since untreated NHDF cells on
tissue culture plastic (TCP) were considered to be at 100% cell viability, luminescence
values were normalized to these at each time point to determine percent cell viability.
Initial Injection
Injectability of the 70:30, 50:50, and 30:70 CPP variations was assessed by fully
ejecting 6 mL of paste from a modified 25 mL repeater pipette syringe using an Instron
Universal Testing Machine (n = 3). Maximum ejection force was recorded and compared
to a clinically relevant maximum ejection force that an individual could achieve of 330 N
[63].
Statistical Analysis
In vitro degradation and biocompatibility testing were analyzed using two-way
Analysis of Variance (ANOVA) followed by Holm-Sidak post hoc tests. Injectability was
analyzed using Kruskal-Wallis one-way ANOVA on ranks followed by a Tukey post hoc
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test. All results are presented as the average ± standard deviation. Evidence of a
statistically significant difference occurred when p < 0.05.
Results
Initial Degradation
Figure 9 below shows the percentage of CPP remaining for all three paste
variations between 1 and 6 days with 24 hour intervals. While the 30:70 CPP did not
show significant degradation until day 6 (p ≤ 0.045), the 50:50 and 70:30 CPP versions
both showed significant degradation after day 1 (p ≤ 0.001). Degradation increased
linearly with acidity, resulting in significantly different degradation rates among all paste
variations at each time point (p < 0.001). At 6 days, both the 50:50 and 70:30 CPP
versions exhibited significantly increased degradation, 29.3% and 56.2% respectively,
compared to the 30:70 CPP (p ≤ 0.001), with the 70:30 version displaying a 26.9%
increase in degradation over the 50:50 CPP.
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Fig. 9 In vitro enzymatic degradation reported as the average ± standard deviation of
weight percent remaining of the sample for 70:30, 50:50, and 30:70 chitosan/PEG paste
variations over 6 days (n = 3). (* represents p < 0.05 versus itself at each time point,
† represents p < 0.05 showing significant degradation through marked day)

Initial Biocompatibility
Percent cell viability results for the 70:30, 50:50, and 30:70 CPP variations as
well as the neutral 1% chitosan sponges are shown in Figure 10. After NHDF exposure to
paste and sponges for 1 and 3 days, the 70:30 CPP had significantly lower cell viability at
both time points than the other paste types tested (p ≤ 0.012). The 30:70 CPP was the
only variation similar to the untreated cells after 24 hours (p = 0.234), but exhibited
significantly lower viability, along with all other samples, than the TCP control after 72
hours (p ≤ 0.048). While the 50:50 CPP and neutral chitosan sponge (negative control)
showed significantly lower viability than the 30:70 CPP after 24 hours (p ≤ 0.002), these
three samples all displayed similar viability after 72 hours (p ≥ 0.559).
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Fig. 10 In vitro direct contact biocompatibility normalized to tissue culture plastic
control reported as the average ± standard deviation of percent cell viability for 70:30,
50:50, and 30:70 chitosan/PEG paste variations and neutral 1% chitosan sponges after 24
and 72 hours (n = 5). (* represents p < 0.05 versus 70:30 paste, † represents p < 0.05
versus all)

Initial Injection
The average ejection force for each CPP variation is shown below in Figure 11.
Ejection forces for the 30:70 CPP were significantly higher than those from the empty
tube used as a control (p = 0.022), whereas the 70:30 and 50:50 CPP versions were not.
While the average ejection force for the 30:70 CPP was below the set cutoff of 330 N
[63], it reached a maximum force well above this at 382 N.
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Fig. 11 Ejection results represented as the average ± standard deviation of force required
to eject air and 70:30, 50:50, and 30:70 chitosan/PEG paste variations from a syringe.
(* represents p < 0.05 versus air)

Discussion
The degradation results showed that all three CPP formulations will degrade over
time, with an increase in degradation and acidic product being directly correlated. The
paste biocompatibility results showed that the 70:30 CPP was the least biocompatible and
that the 50:50 and 30:70 versions exhibited similar, high biocompatibility to the control
neutral sponges after 24 and 72 hours. Though not significantly different, the 30:70 CPP
did exhibit higher biocompatibility than the untreated NHDFs after 24 hours; however, its
biocompatibility was significantly less than that of the NHDFs after 72 hours. While the
30:70 paste had high cell viability, it proved to not be injectable from a syringe. The
highest force reached when ejecting the 30:70 paste was 382 N, which was well over the
clinically relevant maximum ejection force that an individual could achieve of 330 N
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[63]. The 30:70 CPP also proved incapable of staying hydrated; instead of ejecting as a
paste, only the PBS solution previously used to hydrate itself was ejected leaving the
30:70 paste as a dehydrated powder in the syringe. Based on these screening results, it
was decided that research would continue using the 60:40, 50:50, and 40:60
chitosan/PEG paste variations, the data for which is presented in Chapter 3.
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APPENDIX D: COMPARISON OF GAMMA STERILIZED, ETHYLENE OXIDE
STERILIZED, AND NON-STERILE CHITOSAN/PEG PASTE
Objective
Gamma irradiation has been the standard in our laboratory for sterilizing chitosan;
however, biocompatibility results for the chitosan/PEG paste (CPP) were greatly
diminished once sterilized with gamma, as compared to the non-sterile products tested in
Appendix C. The goal of these experiments was to determine any differences that may
exist among the non-sterile, gamma, and ethylene oxide (EtO) sterilization methods in
order to evaluate whether using EtO for sterilization of the CPP would once again make
its biocompatibility comparable to that of the non-sterile (NS) paste. In the event that the
CPP would regularly be sterilized with EtO instead of gamma, neutral control sponges,
sterilized with either gamma or EtO, were also tested to ensure changing sterilization
methods did not result in a negative change to their cell viability either. Biocompatibility,
degradation, and attenuated total reflectance Fourier transform infrared spectrometry
(ATR-FTIR) experiments were all completed to determine any differences among the
gamma sterilized, EtO sterilized, and NS chitosan/PEG paste samples.
Materials and Methods
Detailed materials and methods for fabrication and biocompatibility and
degradation testing of chitosan/PEG paste, chitosan paste, and chitosan sponges can be
found in Appendix A.
Fabrication
The acidic 1% chitosan and neutral 1% chitosan/PEG products were ground
separately into a powder, and combined into three different acidic to neutral ratios:
60:40, 50:50, and 40:60, all of which were gamma sterilized. Extra 50:50 CPP was made
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to be sterilized with EtO or left non-sterile. Acidic and neutral 1% chitosan products
without any PEG added were also ground into a powder, combined into a 50:50 ratio, and
gamma sterilized to form the original chitosan paste formulation developed by Smith et
al. [57]. A 1× phosphate buffered saline (PBS) in ultrapure water solution at 7.5 times the
paste’s dehydrated weight was added to the dehydrated chitosan powder to form a
hydrated chitosan/PEG paste (CPP) or chitosan paste (CP). Acidic 1% chitosan powder
was also used to form a NS 100% acidic chitosan paste used as the positive control in
biocompatibility testing. Neutral 1% chitosan sponges, used as the negative control for
biocompatibility testing, were also gamma or EtO sterilized.
Biocompatibility
In vitro biocompatibility was first assessed by determining the cell viability of
normal human dermal fibroblast (NHDF) cells after being in contact with the gamma
sterilized 60:40, 50:50, and 40:60 CPP variations and neutral 1% chitosan sponges (n =
5). In vitro biocompatibility was later assessed by determining the viability of NHDFs
after being in contact with the NS, gamma sterilized, and EtO sterilized 50:50 CPP,
gamma and EtO sterilized neutral 1% chitosan sponges, and NS 100% acidic chitosan
paste (n = 5). Cytotoxicity was assessed further by comparing the cell viability of gamma
irradiated 50:50 CPP and CP. Cells (passages 4 and 5) were seeded at 2.0 x 104 cells/mL
and allowed to proliferate for 24 hours before inserts containing the samples were placed
in the wells. After 24 and 72 hours of incubation, the inserts were removed and the Cell
Titer-Glo® Luminescent assay was used to measure the luminescent signal at 590 nm
with a plate reader. Since untreated NHDF cells on tissue culture plastic (TCP) were
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considered to be at 100% cell viability, luminescence values were normalized to these at
each time point to determine percent cell viability.
Degradation
In vitro degradation was assessed by enzymatic weight reduction of the NS,
gamma sterilized, and EtO sterilized 50:50 CPP variations over time (n = 4). Paste
samples, 0.75 mL each, remained within the incubator for 1, 2, and 3 days with the
lysozyme solution being completely replaced every 24 hours. The percent CPP remaining
was calculated by dividing this dry, degraded weight by the initial, dehydrated weight
and multiplying by 100. Because the drying process was destructive to the samples, new
samples were used at each time point.
FTIR
Changes to functional groups in chitosan and PEG were noted using ATR-FTIR
to determine any alterations in the chemical compositions of the NS, gamma sterilized,
and EtO sterilized 50:50 CPP (n = 3). Spectra of the 50:50 CPP products were obtained
with a Nicolet iS10 FTIR spectrometer with a diamond ATR crystal (ThermoScientific,
Waltham, MA) using 64 scans with a resolution of 4 cm-1 and analyzed using the Thermo
Scientific OMNICTM Software Suite.
Statistical Analysis
Biocompatibility testing was analyzed using two-way Analysis of Variance
(ANOVA) followed by a Holm-Sidak post hoc test and degradation testing was analyzed
using two-way ANOVA. All results are presented as the average ± standard deviation.
Evidence of a statistically significant difference occurred when p < 0.05.
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Results
Biocompatibility with Gamma Irradiation
Percent cell viability results for the gamma sterilized 60:40, 50:50, and 40:60 CPP
variations and the neutral 1% chitosan sponges are shown in Figure 12. After NHDF
exposure to paste and sponges for 1 and 3 days, all paste variations had significantly
lower cell viability than the neutral sponges (p ≤ 0.011), and all samples had significantly
lower viability than the TCP control (p < 0.001). While the 40:60 and 50:50 CPP
variations exhibited similar viability after 24 hours (p = 0.206), the 50:50 and 60:40 CPP
versions both displayed significantly lower viability than the 40:60 CPP after 72 hours (p
< 0.001) and had significantly decreased cell viability from 24 to 72 hours (p ≤ 0.033).
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Fig. 12 In vitro direct contact biocompatibility normalized to tissue culture plastic control
reported as the average ± standard deviation of percent cell viability for gamma sterilized
60:40, 50:50, and 40:60 chitosan/PEG paste variations and neutral 1% chitosan sponges
after 24 and 72 hours (n = 5). (* represents p < 0.05 versus all at respective time point,
† represents p < 0.05 versus each other)
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Biocompatibility for Sterilization Method Comparison
Figure 13 shows the percent cell viability results for the NS, gamma sterilized,
and EtO sterilized 50:50 CPP, gamma and EtO sterilized neutral 1% chitosan sponges,
and NS 100% acidic chitosan paste. After NHDF exposure to paste and sponges for 1 and
3 days, the 100% acidic paste and the gamma 50:50 CPP displayed similar viability after
24 hours (p = 0.106), as well as the lowest cell viability after 24 and 72 hours. While the
NS 50:50 had significantly higher cell viability than (p = 0.011) and the sponges
exhibited similar viability to the TCP control after 24 hours (p ≥ 0.124), only the NS
50:50 displayed similar viability to the untreated cells after 72 hours (p = 0.161) while all
other samples demonstrated significantly lower viability (p ≤ 0.005). Although the EtO
50:50 CPP displayed significantly lower cell viability than the gamma and EtO sterilized
control sponges after 24 hours (p ≤ 0.001), all three displayed similar, high cell viability
after 72 hours (p ≥ 0.308).
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Fig. 13 In vitro direct contact biocompatibility normalized to tissue culture plastic control
reported as the average ± standard deviation of percent cell viability for gamma sterilized,
EtO sterilized, and non-sterile 50:50 chitosan/PEG paste variations, gamma and EtO
sterilized neutral 1% chitosan sponges, and non-sterile 100% acidic chitosan paste after
24 and 72 hours (n = 5). (* represents p < 0.05 versus all at same time point,
** represents p < 0.05 versus all except §, † represents p < 0.05 versus untreated cells)

Micrographs of the cells after exposure to the chitosan and chitosan/PEG samples
are shown in Figure 14. It can clearly be seen that the gamma irradiated 50:50 CPP, along
with the NS 100% acidic CP, have a multitude of large degradation particles present
whereas the NS and EtO sterilized 50:50 CPP variations are similar to the neutral control
sponges with minimal degradation particles present and long, spindle-like cells
characteristic of healthy fibroblasts.
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Fig. 14 NHDF cells after 72 hours of exposure to non-sterile, gamma sterilized, and EtO
sterilized 50:50 chitosan/PEG paste variations, non-sterile 100% acidic chitosan paste,
and gamma and EtO sterilized neutral 1% chitosan sponges.
Percent cell viability for the gamma sterilized 50:50 chitosan and chitosan/PEG
paste formulations can be seen in Figure 15A. The gamma irradiated 50:50 CPP
demonstrated significantly lower viability than the 50:50 CP (p < 0.001) and, as seen in
the micrographs in Figure 15B, the gamma irradiated 50:50 containing PEG had a
considerable amount of large degradation particles present whereas the gamma irradiated
50:50 without PEG did not and instead presented long, spindle-like cells characteristic of
healthy fibroblasts.
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Fig. 15A-B (A) In vitro direct contact biocompatibility normalized to tissue culture
plastic control reported as the average ± standard deviation of percent cell viability
(n = 5) after 24 and 72 hours (* represents p < 0.05 versus all at same time point) and
(B) NHDF cells after 72 hours of exposure to gamma sterilized 50:50 chitosan/PEG and
chitosan paste variations.
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Degradation for Sterilization Method Comparison
The percentage of CPP remaining for the NS, gamma sterilized, and EtO
sterilized 50:50 CPP over 3 days is shown in Figure 16 below. All 50:50 CPP variations
degraded significantly over 3 days, with the EtO sterilized degrading significantly more
than the gamma sterilized, and the gamma sterilized degrading significantly more than
the non-sterile paste (p < 0.001). By day 3, the NS 50:50 CPP had degraded to 40.4%
remaining, the gamma sterilized to 29.9% remaining, and the EtO sterilized had degraded
completely.
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Fig. 16 In vitro enzymatic degradation reported as the average ± standard deviation of
weight percent remaining of the sample for gamma sterilized, EtO sterilized, and nonsterile 50:50 chitosan/PEG paste variations over 3 days (n = 4). (* represents p < 0.05
versus each other)

68

FTIR for Sterilization Method Comparison
Figure 17 below shows the FTIR spectra of chitosan powder and gamma
sterilized, EtO sterilized, and non-sterile 50:50 CPP variations. All 50:50 CPP samples
exhibited characteristic chitosan peaks near 3360, 3293, 1061, and 1025 cm-1 [51, 57]
with characteristic peaks at 1650 and 1590 cm-1 shifted to 1545 and 1400 cm-1,
respectively [57]. A characteristic peak common to chitosan and 6,000 g/mol PEG at
2879 cm-1 was also seen in all 50:50 CPP samples [51]. Characteristic peaks of PEG
should be seen around 1281, 1096, 963, and 841 cm-1 [30]; however, the spectra do not
conclusively indicate peaks at 1281, 1096, or 963 cm-1 and there is no indication of a
peak at 841 cm-1. In all of the 50:50 CPP samples, new peaks also appeared at 2980 and
1650 cm-1 with the intensity of the peaks increasing from NS, to gamma, to EtO; these
new peaks indicate a chemical reaction between the chitosan and PEG materials.
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Fig. 17 Stacked and averaged ATR-FTIR absorbance spectra for chitosan powder and
50:50 EtO, gamma, and NS chitosan/PEG paste (n = 3).

Discussion
As previously stated, the goal of this experiment was to determine any differences
that may exist among the non-sterile, gamma, and EtO sterilization methods for the
chitosan/PEG paste through biocompatibility, degradation, and FTIR analysis. The
biocompatibility results showed that the non-sterile paste is the most biocompatible and
the only option with similar cell viability to the untreated cells; however, the paste must
be sterilized in order to be used inside the body. The EtO sterilized 50:50 CPP, therefore,
is the most viable option.
The EtO 50:50 CPP displayed 86.3% cell viability after 72 hours, which was
similar to the EtO and gamma sterilized neutral control sponges with 83.9% and 79.2%
cell viability, respectively, and significantly higher than the gamma 50:50 CPP with
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65.8% cell viability. The gamma irradiated 50:50 chitosan paste without PEG also
displayed significantly higher cell viability than the 50:50 chitosan/PEG paste at 77.1%
after 72 hours. Upon microscopic examination, there was a considerable increase in
degradation particles present within the wells containing the gamma versus the EtO 50:50
CPP. This would seem to indicate that the gamma irradiated CPP degrades faster. As seen
in the degradation experiment, the EtO sterilized paste actually degrades the fastest with
0% remaining after 3 days as compared to 29.9% remaining of the gamma sterilized and
40.4% remaining of the non-sterile paste. Also, the gamma 50:50 paste without PEG did
not experience the same vast increase in degradation particles during cytotoxicity testing
as the paste formulation with PEG. These degradation results, along with the
biocompatibility results, led us to infer that the decreased cell viability of the gamma
sterilized chitosan/PEG paste was due to larger degradation particles being released than
those from the EtO sterilized paste because of an interaction happening between the
gamma irradiation and the PEG.
In addition, increased sensitivity to radiation damage by gamma irradiation in the
presence of PEG has been reported in literature, attributed to chain scission reactions that
form polymeric free radicals. The extent of these chain scissions is exacerbated when the
polymers are sterilized and stored exposed to oxygen, particularly when the molecules
contain cationic esters, such as those found in chitosan [23]. These effects continue after
the irradiation process, as materials react with oxygen and generate peroxyl free radicals
that increase degradation reactions. Crosslinking is also increased with irradiation and has
been reported to affect the swelling performance of chitosan hydrogels [25].
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While the FTIR results for the chitosan/PEG paste did not confirm any of the
characteristic peaks for PEG, Parker et al. also noted that the peaks at 1281, 1096, and
963 cm-1 did not appear and the peak at 841 cm-1 was minimal for the neutral chitosan
sponge modified with 6,000 g/mol PEG, which is the same formulation as that used for
the neutral portion of the CPP [51]. The characteristic peaks for chitosan also appeared,
with noticeable shifts in the peaks at 1650 to 1545 cm-1 and 1590 to 1400 cm-1, which
were also reported by Smith et al. for the unmodified chitosan paste [63]. The FTIR
spectra of the 50:50 CPP samples also displayed two new peaks at 2980 and 1650 cm-1,
neither of which was reported by Parker or Smith et al. These new peaks indicate a
chemical reaction between the chitosan and PEG materials, possibly occurring during the
neutralization or sterilization process. It can be inferred that the chemical change
indicated by these peaks does not affect the biocompatibility of the paste since the
intensity of the peaks for the gamma irradiated 50:50 CPP is between the intensities of
the NS and EtO sterilized products. In conclusion, ethylene oxide sterilized CPP has
significantly increased biocompatibility over the gamma sterilized CPP, but further
material characterization tests should be run in order to determine the reasoning behind
this change.
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APPENDIX E: BIOCOMPATIBILITY OF GAMMA STERILIZED
CHITOSAN/PEG PASTE USING 8,000 G/MOL PEG
Objective
The procedure for making acidic sponges takes up to four days and neutralization
adds an additional three, making it a seven day process to procure neutral sponges for the
chitosan/PEG paste formulation. The goal of this experiment was to evaluate the
biocompatibility of an acidic chitosan sponge modified with 8,000 g/mol PEG to be used
as a fully acidic chitosan/PEG paste in order to eliminate the need for neutralization. The
8,000 g/mol PEG modified chitosan sponge was previously formulated and tested by
Parker et al., and was shown to exhibit high biocompatibility, degradability, and a desired
antibiotic/antifungal elution profile [50, 51]. Eliminating the neutralization step in the
sponge-making process would cut the fabrication time by nearly half and remove the time
consuming process of mixing acidic and neutral products in specific ratios.
Materials and Methods
Detailed materials and methods for fabrication and biocompatibility testing of
chitosan/PEG paste and sponges can be found in Appendix A.
Fabrication
For the chitosan/PEG paste, 0.5% w/v of 8,000 g/mol PEG was dissolved in a
0.5% or 1% v/v acetic acid in water solution, and following dissolution, 0.5% w/v of
chitosan was dissolved in the same solution. The chitosan/PEG solution was cast, frozen
overnight, and lyophilized to create acidic, dehydrated sponges. Some of the 1% acid
8,000 sponges were set aside to be used as the control while the remaining 1% acid and
all of the 0.5% acid 8,000 sponges were ground separately into a powder and hydrated
with a 1× phosphate buffered saline (PBS) in ultrapure water solution at 7.5 times the
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paste’s dehydrated weight in order to form a hydrated chitosan/PEG paste (CPP). All
samples used were sterilized with gamma irradiation.
Biocompatibility
In vitro biocompatibility was assessed by determining the cell viability of normal
human dermal fibroblast (NHDF) cells after being in contact with the 0.5% and 1% acid
8,000 CPP variations as well as 1% acid 8,000 chitosan/PEG sponges (n = 5). Cells
(passage 4) were seeded at 4.63 x 104 cells/mL and allowed to proliferate for 24 hours
before inserts containing the samples were placed in the wells. After 24 and 72 hours of
incubation, the inserts were removed and the Cell Titer-Glo® Luminescent assay was
used to measure the luminescent signal at 590 nm with a plate reader. Since untreated
NHDF cells on tissue culture plastic (TCP) were considered to be at 100% cell viability,
luminescence values were normalized to these at each time point to determine percent
cell viability.
Statistical Analysis
In vitro biocompatibility testing was analyzed using a two-way Analysis of
Variance (ANOVA) followed by a Holm-Sidak post hoc test. Results are presented as the
average ± standard deviation. Evidence of a statistically significant difference occurred
when p < 0.05.
Results
Figure 18 shows the percent cell viability results for the 1% acid 8,000 CPP, 0.5%
acid 8,000 CPP, and the 1% acid 8,000 chitosan/PEG sponges (CPS). After NHDF
exposure to paste and sponges for 1 and 3 days, the 1% acid 8,000 CPP had significantly
lower cell viability at both time points than all other samples tested (p < 0.001). The 1%
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acid 8,000 CPS were the only sample similar to the untreated cells after 24 hours (p =
0.058), but exhibited significantly lower viability, along with all other samples, than the
TCP control after 72 hours (p < 0.001). Both paste versions also displayed significantly
lower viability than the control 1% acid 8,000 CPS after 24 and 72 hours (p < 0.001).
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Fig. 18 In vitro direct contact biocompatibility normalized to tissue culture plastic
control reported as the average ± standard deviation of percent cell viability for 0.5% and
1% acid 8,000 chitosan/PEG paste variations and 1% acid 8,000 chitosan/PEG sponges
after 24 and 72 hours (n = 5). (* represents p < 0.05 versus all, † represents p < 0.05
versus all except untreated cells)

Discussion
The biocompatibility results for the fully acidic chitosan paste modified with
8,000 g/mol polyethylene glycol were less than desirable, with the modified control
sponge showing 80.7% cell viability and the 1% and 0.5% acid 8,000 CPP variations
only displaying average cell viabilities of 37.6% and 56.2% after 72 hours, respectively.
Due to their low viability, these formulations were originally discarded and research was
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continued using the 60:40, 50:50, and 40:60 CPP variations; however, it is now known
that the 0.5% acid 8,000 CPP still has the potential to be a viable paste option.
As previously stated, all of these samples were sterilized using gamma irradiation;
and as shown in Appendix D, gamma sterilization can be detrimental to the viability of
the chitosan/PEG paste and ethylene oxide gas (EtO) should instead be used for
sterilization purposes. It was reported in Appendix D that the gamma sterilized 50:50
CPP cell viability can be as low as 52.4% after 72 hours, which is slightly lower than the
56.2% cell viability of the 0.5% acid 8,000 CPP reported here in Appendix D; however,
when the sterilization method was switched to EtO, the 50:50 CPP displayed significantly
higher cell viability at 86.3% after 72 hours, which was also similar to the neutral control
sponge tested. These results indicate that there is potential for the 0.5% acid 8,000 CPP to
also show a significant increase in cell viability and similarity to the neutral sponge
control if the CPP is sterilized with EtO instead of gamma.
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APPENDIX F: IACUC ANIMAL USE PROTOCOL APPROVAL LETTER
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